Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Study Using IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer, Following Disease Progression on Docetaxel-Based Chemotherapy

Study:

A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy

Rationale:

n/a

Purpose:

The purpose of this study is to determine whether IMC-A12 or IMC-1121B with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Metastatic Androgen-Independent Prostate Cancer Drug: IMC-1121B and IMC-A12 Phase 2

Verified by ImClone Systems September, 2008

Sponsored by: ImClone Systems
Information provided by: ImClone Systems
ClinicalTrials.gov identifier: NCT00683475

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site